Pfizer (PFE) Tops Q4 EPS by 1c, FY EPS Guidance Misses Consensus
Pfizer (NYSE: PFE) reported Q4 EPS of $0.64, $0.01 better than the analyst estimate of $0.63. Revenue for the quarter came in at $13.98 billion versus the consensus estimate of $13.91 billion.
Pfizer sees FY2019 EPS of $2.82-$2.92, versus the consensus of $3.04. Pfizer sees FY2019 revenue of $52-54 billion, versus the consensus of $54.36 billion.
- Financial guidance for Adjusted Other (Income)/Deductions(2) and Adjusted Diluted EPS(2) now excludes the impact of realized and unrealized gains and losses on investments in equity securities. In 2018, Pfizer’s 2018 financial results included net gains on investments in equity securities, which favorably impacted Adjusted Other (Income)/Deductions(2) by $586 million and Adjusted Diluted EPS(2) by approximately $0.08.
For earnings history and earnings-related data on Pfizer (PFE) click here.